alendronate has been researched along with Necrosis in 10 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the Managing Avascular Necrosis Treatments: an Interventional Study ( MANTIS ) trial was to evaluate the clinical effectiveness and cost-effectiveness of a 12-month course of alendronate in the treatment of avascular necrosis." | 9.51 | Assessing a 12-month course of oral alendronate for adults with avascular necrosis of the hip: MANTIS RCT with internal pilot. ( Akanni, M; Barber, V; Beard, D; Board, T; Davies, L; Dritsaki, M; Dutton, SJ; Glyn-Jones, S; Javaid, MK; Kerslake, R; Khanduja, V; Knight, R; McBryde, C; Newton, J; Peckham, N; Rombach, I; Sexton, S; Skinner, J, 2022) |
| " In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis." | 7.72 | Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004) |
| "The study objective was to evaluate the effect on osteoblast growth of high concentrations of three nitrogen-containing bisphosphonates (pamidronate, alendronate, and ibandronate) and one non-nitrogen-containing bisphosphonate (clodronate), using the MG-63 cell line as an osteoblast model, in order to determine the role of osteoblasts in bisphosphonate-related osteonecrosis of the jaw (BRONJ)." | 3.81 | High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. ( De Luna-Bertos, E; García-Martínez, O; Manzano-Moreno, FJ; Ramos-Torrecillas, J; Ruiz, C, 2015) |
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| " In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis." | 3.72 | Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "This osteolysis was evaluated by measuring the increased area of bone resorption in reduced opacity to radiograph and histologic study." | 1.28 | Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. ( Koiso, K; Miyagawa, I; Nemoto, R; Satou, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glyn-Jones, S | 1 |
| Javaid, MK | 1 |
| Beard, D | 1 |
| Newton, J | 1 |
| Kerslake, R | 1 |
| McBryde, C | 1 |
| Board, T | 1 |
| Dutton, SJ | 1 |
| Dritsaki, M | 1 |
| Khanduja, V | 1 |
| Akanni, M | 1 |
| Sexton, S | 1 |
| Skinner, J | 1 |
| Peckham, N | 1 |
| Knight, R | 1 |
| Rombach, I | 1 |
| Davies, L | 1 |
| Barber, V | 1 |
| Möller, B | 1 |
| Wiltfang, J | 1 |
| Acil, Y | 1 |
| Gierloff, M | 1 |
| Lippross, S | 1 |
| Terheyden, H | 1 |
| Manzano-Moreno, FJ | 1 |
| Ramos-Torrecillas, J | 1 |
| De Luna-Bertos, E | 1 |
| Ruiz, C | 1 |
| García-Martínez, O | 1 |
| Oizumi, T | 1 |
| Funayama, H | 1 |
| Yamaguchi, K | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Yamamoto, M | 1 |
| Kuroishi, T | 1 |
| Kumamoto, H | 1 |
| Sasaki, K | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Tipton, DA | 1 |
| Seshul, BA | 1 |
| Dabbous, MKh | 1 |
| Marcuzzi, A | 1 |
| Piscianz, E | 1 |
| Girardelli, M | 1 |
| Crovella, S | 1 |
| Pontillo, A | 1 |
| Sevcik, MA | 1 |
| Luger, NM | 1 |
| Mach, DB | 1 |
| Sabino, MA | 1 |
| Peters, CM | 1 |
| Ghilardi, JR | 1 |
| Schwei, MJ | 1 |
| Röhrich, H | 1 |
| De Felipe, C | 1 |
| Kuskowski, MA | 1 |
| Mantyh, PW | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| De Ponte, FS | 1 |
| Rogers, MJ | 1 |
| Chilton, KM | 1 |
| Coxon, FP | 1 |
| Lawry, J | 1 |
| Smith, MO | 1 |
| Suri, S | 1 |
| Russell, RG | 1 |
| Nemoto, R | 1 |
| Satou, S | 1 |
| Miyagawa, I | 1 |
| Koiso, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for alendronate and Necrosis
| Article | Year |
|---|---|
Assessing a 12-month course of oral alendronate for adults with avascular necrosis of the hip: MANTIS RCT with internal pilot.
Topics: Adult; Alendronate; Cost-Benefit Analysis; Humans; Necrosis; Technology Assessment, Biomedical; Trea | 2022 |
9 other studies available for alendronate and Necrosis
| Article | Year |
|---|---|
Prevention of the surface resorption of bone grafts by topical application of bisphosphonate on different carrier materials.
Topics: Administration, Topical; Alendronate; Alveolar Ridge Augmentation; Animals; Bone Resorption; Cattle; | 2014 |
High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis.
Topics: Alendronate; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservatio | 2015 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6.
Topics: Alendronate; Analysis of Variance; Bone Density Conservation Agents; Bone Remodeling; Cells, Culture | 2011 |
Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes.
Topics: Alendronate; Animals; Apoptosis; Biomarkers; Biosynthetic Pathways; Caspase 1; Caspase 3; Caspase In | 2011 |
Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis.
Topics: Activating Transcription Factor 3; Alendronate; Animals; Behavior, Animal; Biomarkers, Tumor; Bone N | 2004 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.
Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Division; Cel | 1996 |
Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Female; Mice; Mice, Inbred C3H; Necrosis; Neop | 1991 |